Department of Pharmacology, Division of Neuroscience, Shrimati Kishoritai Bhoyar College of Pharmacy, Nagpur, India.
Government Colleges of Pharmacy , Amravati, India.
Alcohol Clin Exp Res. 2019 Apr;43(4):747-757. doi: 10.1111/acer.13972. Epub 2019 Mar 6.
Locomotor sensitization to repeated ethanol (EtOH) administration is proposed to play a role in early and recurring steps of addiction. The present study was designed to examine the effect of agmatine on EtOH-induced locomotor sensitization in mice.
Mice received daily single intraperitoneal injection of EtOH (2.5 g/kg, 20 v/v) for 7 consecutive days. Following a 3-day EtOH-free phase, the mice were challenged with EtOH on day 11 with a single injection of EtOH. Agmatine (10 to 40 μg/mouse), endogenous agmatine enhancers (l-arginine [80 μg/mouse], arcaine [50 μg/mouse], aminoguanidine [25 μg/mouse]), and imidazoline receptor agonist/antagonists were injected (intracerebroventricular [i.c.v.]) either daily before the injection of EtOH during the 7-day development phase or on days 8, 9, and 10 (EtOH-free phase). The horizontal locomotor activity was determined on days 1, 3, 5, 7, and 11.
Agmatine (20 to 40 μg/mouse) administration for 7 days (development phase) significantly attenuated the locomotor sensitization response of EtOH challenge on day 11. Further, the agmatine administered only during EtOH-free period (days 8, 9, and 10) also inhibited the enhanced locomotor activity on the 11th day to EtOH challenge as compared to control mice indicating blockade of expression of sensitization. Daily treatment (i.c.v.) with endogenous agmatine enhancers like l-arginine (80 μg/mouse) or arcaine (50 μg/mouse) and aminoguanidine (25 μg/mouse) restrained the development as well as expression of sensitization to EtOH. Imidazoline I receptor agonist, moxonidine, and I agonist, 2-BFI, not only decreased the development and expression of locomotor sensitization but also potentiated the effect of agmatine when employed in combination. Importantly, I receptor antagonist, efaroxan, and I antagonist, idazoxan, blocked the effect of agmatine, revealing the involvement of imidazoline receptors in agmatine-mediated inhibition of EtOH sensitization.
Inhibition of EtOH sensitization by agmatine is mediated through imidazoline receptors and project agmatine and imidazoline agents in the pharmacotherapy of alcohol addiction.
反复给予乙醇(EtOH)会引起运动敏化,这被认为在成瘾的早期和反复出现的步骤中发挥作用。本研究旨在研究胍丁胺对小鼠 EtOH 诱导的运动敏化的影响。
小鼠每天接受单次腹腔注射 EtOH(2.5 g/kg,20 v/v),连续 7 天。在 3 天的 EtOH 无药期后,第 11 天用单次 EtOH 注射对小鼠进行挑战。胍丁胺(10 至 40μg/只)、内源性胍丁胺增强剂(l-精氨酸[80μg/只]、arcaine[50μg/只]、氨基胍[25μg/只])和咪唑啉受体激动剂/拮抗剂在 7 天的发展阶段,每天在 EtOH 注射前注射(脑室内[icv]),或在第 8、9 和 10 天(EtOH 无药期)注射。在第 1、3、5、7 和 11 天测定水平运动活动。
胍丁胺(20 至 40μg/只)连续 7 天给药(发展阶段)可显著减弱第 11 天 EtOH 挑战时的运动敏化反应。此外,与对照组小鼠相比,仅在 EtOH 无药期(第 8、9 和 10 天)给予胍丁胺也抑制了第 11 天 EtOH 挑战时的运动活性增强,表明敏化表达的阻断。内源性胍丁胺增强剂,如 l-精氨酸(80μg/只)或 arcaine(50μg/只)和氨基胍(25μg/只)的每日治疗(icv)抑制了 EtOH 的发展和敏化表达。咪唑啉 I 受体激动剂莫索尼定和 I 激动剂 2-BFI 不仅降低了运动敏化的发展和表达,而且在联合使用时增强了胍丁胺的作用。重要的是,咪唑啉 I 受体拮抗剂 efaroxan 和 I 拮抗剂 idazoxan 阻断了胍丁胺的作用,表明咪唑啉受体参与了胍丁胺介导的 EtOH 敏化抑制。
胍丁胺对 EtOH 敏化的抑制是通过咪唑啉受体介导的,并且在酒精成瘾的药物治疗中提出了胍丁胺和咪唑啉药物。